NO20002153L - Aminotiazol-inhibitorer for cyklin-avhengige kinaser - Google Patents

Aminotiazol-inhibitorer for cyklin-avhengige kinaser

Info

Publication number
NO20002153L
NO20002153L NO20002153A NO20002153A NO20002153L NO 20002153 L NO20002153 L NO 20002153L NO 20002153 A NO20002153 A NO 20002153A NO 20002153 A NO20002153 A NO 20002153A NO 20002153 L NO20002153 L NO 20002153L
Authority
NO
Norway
Prior art keywords
cyclin
dependent kinases
aminothiazole inhibitors
aminothiazole
inhibitors
Prior art date
Application number
NO20002153A
Other languages
English (en)
Other versions
NO20002153D0 (no
NO316773B1 (no
Inventor
Kyoung S Kim
S David Kimball
Michael A Poss
Raj Narain Misra
Zhen-Wei Cai
David B Rawlins
Kevin Webster
John T Hunt
Wen-Ching Han
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20002153D0 publication Critical patent/NO20002153D0/no
Publication of NO20002153L publication Critical patent/NO20002153L/no
Publication of NO316773B1 publication Critical patent/NO316773B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
NO20002153A 1997-11-12 2000-04-27 Aminotiazol-inhibitorer for cyklin-avhengige kinaser, farmasoytisk blanding og anvendelse derav NO316773B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6519597P 1997-11-12 1997-11-12
PCT/US1998/023197 WO1999024416A1 (en) 1997-11-12 1998-11-02 Aminothiazole inhibitors of cyclin dependent kinases

Publications (3)

Publication Number Publication Date
NO20002153D0 NO20002153D0 (no) 2000-04-27
NO20002153L true NO20002153L (no) 2000-05-11
NO316773B1 NO316773B1 (no) 2004-05-03

Family

ID=22060972

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002153A NO316773B1 (no) 1997-11-12 2000-04-27 Aminotiazol-inhibitorer for cyklin-avhengige kinaser, farmasoytisk blanding og anvendelse derav

Country Status (32)

Country Link
US (1) US6040321A (no)
EP (1) EP1042307B1 (no)
JP (1) JP4344084B2 (no)
KR (2) KR100454426B1 (no)
CN (1) CN1160343C (no)
AR (1) AR017182A1 (no)
AT (1) ATE374771T1 (no)
AU (1) AU730607B2 (no)
BR (1) BR9814124A (no)
CA (1) CA2309551C (no)
CO (1) CO4990957A1 (no)
CY (1) CY1107509T1 (no)
CZ (1) CZ297907B6 (no)
DE (1) DE69838515T2 (no)
DK (1) DK1042307T3 (no)
EG (1) EG24028A (no)
ES (1) ES2296347T3 (no)
HU (1) HUP0004559A3 (no)
ID (1) ID23983A (no)
IL (1) IL135589A (no)
MY (1) MY120779A (no)
NO (1) NO316773B1 (no)
NZ (1) NZ503828A (no)
PE (1) PE131699A1 (no)
PL (1) PL204642B1 (no)
PT (1) PT1042307E (no)
RU (1) RU2211839C2 (no)
TR (1) TR200001344T2 (no)
TW (1) TW593292B (no)
UY (1) UY25239A1 (no)
WO (1) WO1999024416A1 (no)
ZA (1) ZA9810332B (no)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6414156B2 (en) * 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
US6214852B1 (en) * 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6337338B1 (en) * 1998-12-15 2002-01-08 Telik, Inc. Heteroaryl-aryl ureas as IGF-1 receptor antagonists
US20040171632A1 (en) * 1998-12-22 2004-09-02 Gowan Richard Carleton Combination chemotherapy
ID30250A (id) * 1998-12-22 2001-11-15 Warner Lambert Co Kemoterapi kombinasi
WO2000061552A1 (en) * 1999-04-07 2000-10-19 Santen Pharmaceutical Co., Ltd. N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE AND USE THEREOF AS TNF-α PRODUCTION INHIBITOR
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
ID30460A (id) 1999-04-15 2001-12-06 Bristol Myers Squibb Co Inhibitor-inhibitor protein siklik tirosin kinase
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
DE60024631T2 (de) * 1999-07-26 2006-06-14 Banyu Pharma Co Ltd Biaryl-harnstoff-derivate
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
MY125768A (en) * 1999-12-15 2006-08-30 Bristol Myers Squibb Co N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6515004B1 (en) 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6392053B2 (en) 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
WO2001056567A1 (en) * 2000-02-04 2001-08-09 Novo Nordisk A/S 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors
IT1317826B1 (it) 2000-02-11 2003-07-15 Dompe Spa Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8.
CA2398446A1 (en) 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinases
US6534531B2 (en) * 2000-04-27 2003-03-18 Bristol-Myers Squibb Company Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
AU2001264376A1 (en) * 2000-06-15 2001-12-24 Chaconne Nsi Co., Ltd. Urea derivative useful as an anti-cancer agent and process for preparing same
CZ2003237A3 (cs) * 2000-07-26 2003-06-18 Bristol-Myers Squibb Company N-(5-{[(5-Alkyl-2-oxazolyl)methyl]thio}-2-thiazolyl) karboxamidy jako inhibitory cyklin-dependentních kináz
WO2002012250A2 (en) * 2000-08-09 2002-02-14 Agouron Pharmaceuticals, Inc. Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US20020173507A1 (en) * 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
DE60117605T2 (de) 2000-12-21 2006-12-07 Bristol-Myers Squibb Co. Thiazolyl-inhibitoren von tyrosinkinasen der tec-familie
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
EP1938821B1 (en) 2001-01-25 2016-03-30 Bristol-Myers Squibb Company Dosage forms of an epothilone analogue for the treatment of cancer
SI1372650T1 (sl) * 2001-03-19 2009-04-30 Novartis Ag Kombinacije, ki obsegajo antidiaroično sredstvo in epotilon ali epotilonski derivat
EP1256578B1 (en) 2001-05-11 2006-01-11 Pfizer Products Inc. Thiazole derivatives and their use as cdk inhibitors
AU2002342878A1 (en) * 2001-05-16 2002-11-25 Axxima Pharmaceuticals Ag Pyridylpyrimidine derivatives as effective compounds against prion diseases
ES2333412T3 (es) 2001-05-25 2010-02-22 Bristol-Myers Squibb Company Derivados de hidantoina como inhibidores de metaloproteinasas de matriz.
HN2002000156A (es) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
BR0211265A (pt) * 2001-07-19 2004-07-20 Pharmacia Italia Spa Derivados de fenilacetamido-tiazol, processo para sua preparação e o seu uso como agentes antitumor
EE200400074A (et) * 2001-08-31 2004-06-15 Bristol-Myers Squibb Company Koostised ning nende kasutamine proliferatiivsetehaiguste raviks
US7405234B2 (en) * 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
EP1531815B1 (en) 2002-06-27 2014-09-24 Novo Nordisk A/S Glucokinase activators
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
JP2006500391A (ja) * 2002-09-04 2006-01-05 シェーリング　コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
NZ539161A (en) * 2002-09-04 2006-05-26 Schering Corp Pyrazolopyrimidines as cyclin dependent kinase inhibitors
ATE364608T1 (de) * 2002-09-04 2007-07-15 Schering Corp Pyrazolopyrimidine als hemmstoffe cyclin- abhängiger kinasen
US7205308B2 (en) * 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US7161003B1 (en) * 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
AR041136A1 (es) * 2002-09-04 2005-05-04 Pharmacopeia Drug Discovery Pirazolopirimidinas como inhibidores de cinasas dependientes de clclinas
ATE374768T1 (de) 2002-10-03 2007-10-15 Hoffmann La Roche Indole-3-carbonsaüreamide als glucokinase (gk) aktivatoren
RU2005113713A (ru) * 2002-10-03 2006-01-20 Новартис АГ (CH) Замещенные (тиазол-2-ил)амиды или сульфонамиды в качестве активаторов глюкокиназы, которые могут применяться при лечении диабета типа 2
RU2005115842A (ru) * 2002-10-24 2006-03-10 Мерк Патент ГмбХ (DE) Производные метиленмочевины
US7632858B2 (en) * 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
JP2007507204A (ja) * 2003-07-29 2007-03-29 ブリストル−マイヤーズ　スクイブ　カンパニー サイクリン依存性キナーゼモデュレーションのバイオマーカー
US6949895B2 (en) * 2003-09-03 2005-09-27 Axcelis Technologies, Inc. Unipolar electrostatic quadrupole lens and switching methods for charged beam transport
US7256208B2 (en) * 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
WO2005058341A2 (en) * 2003-12-11 2005-06-30 Theravance, Inc. Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
DK1723128T3 (da) 2004-01-06 2013-02-18 Novo Nordisk As Heteroarylurinstoffer og deres anvendelse som glucokinaseaktivatorer
WO2005072731A1 (en) * 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
WO2005075435A1 (en) * 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US20050182105A1 (en) * 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
US7820702B2 (en) * 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
EP1568368A1 (en) * 2004-02-26 2005-08-31 Schering Aktiengesellschaft Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7388027B2 (en) * 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7211576B2 (en) 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
HRP20080349T3 (hr) 2004-11-18 2009-01-31 Bristol-Myers Squibb Company Zrna premazana enteričkom smjesom koja sadrže iksabepilon
US20100105745A1 (en) * 2005-01-04 2010-04-29 Toshinari Minamoto Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta
JPWO2006073202A1 (ja) * 2005-01-04 2008-08-07 国立大学法人金沢大学 ＧＳＫ３β阻害効果に基づくがんの抑制および抗がん剤の評価方法
ATE547396T1 (de) 2005-07-08 2012-03-15 Novo Nordisk As Dicycloalkylcarbamoyl-harnstoffe als glucokinase- aktivatoren
RU2443691C2 (ru) * 2005-07-14 2012-02-27 Транстех Фарма, Инк. Мочевинные активаторы глюкокиназы
EP1948657A1 (en) * 2005-11-15 2008-07-30 Vertex Pharmaceuticals Incorporated Azaindazoles useful as inhibitors of kinases
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7888504B2 (en) * 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
WO2008049856A2 (en) * 2006-10-25 2008-05-02 Ingenium Pharmaceuticals Gmbh Methods of treating pain using cdk inhibitors
BRPI0718360A2 (pt) 2006-12-04 2013-11-12 Univ Illinois "composições e métodos para o tratamento do câncer com cupredoxinas e dna rico em cpg"
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
SG185414A1 (en) 2010-05-12 2012-12-28 Univ Vanderbilt Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
ES2986590T3 (es) 2010-06-14 2024-11-12 Scripps Research Inst Reprogramación de células hacia un nuevo destino
NZ611410A (en) * 2010-11-01 2016-02-26 Romark Lab Lc Alkylsulfinyl-substituted thiazolide compounds
WO2012100206A2 (en) 2011-01-20 2012-07-26 Board Of Regents, The University Of Texas System Mri markers, delivery and extraction systems, and methods of manufacture and use thereof
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
US8940742B2 (en) * 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN104768962B (zh) 2012-11-17 2017-04-05 北京市丰硕维康技术开发有限责任公司 离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
US9452170B2 (en) 2013-03-15 2016-09-27 The California Institute For Biomedical Research Compounds and methods for inducing chondrogenesis
PL3052485T3 (pl) 2013-10-04 2022-02-28 Infinity Pharmaceuticals, Inc. Związki heterocykliczne i ich zastosowania
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2943075C (en) 2014-03-19 2023-02-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
HK1245260A1 (zh) 2014-12-23 2018-08-24 Dana-Farber Cancer Institute, Inc. 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂
JP6861166B2 (ja) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
US11142507B2 (en) 2015-09-09 2021-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
NZ740616A (en) 2015-09-14 2023-05-26 Infinity Pharmaceuticals Inc Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
GEP20207128B (en) * 2016-04-06 2020-07-10 Molecules Gm Innovative Aminothiazole derivatives useful as antiviral agents
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2018068832A1 (en) 2016-10-11 2018-04-19 Euro-Celtique S.A. Hodgkin lymphoma therapy
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
KR102708082B1 (ko) * 2017-10-05 2024-09-19 이노베이티브 몰리큘스 게엠베하 항바이러스 화합물로서 치환된 티아졸의 거울상 이성질체
WO2019241089A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
EP3897626B1 (en) 2018-12-18 2025-09-10 Mundipharma International Corporation Limited Tinostamustine for treating multiple myeloma
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
JP2023545588A (ja) * 2020-10-16 2023-10-30 ツェーエムエム－フォルシュングスツェントルム フュア モレクラレ メディツィン ゲーエムベーハー ヘテロ環式カリンｒｉｎｇユビキチンリガーゼ化合物及びその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1088049A (en) * 1975-06-03 1980-10-21 Takashi Masugi 3-substituted-7-substituted alkanamido-3-cephem-4- carboxylic acid compounds and processes for preparation thereof
NO831160L (no) * 1982-04-08 1983-10-10 Erba Farmitalia Fremstilling av substituerte penem-derivater
JPS6339868A (ja) * 1986-08-04 1988-02-20 Otsuka Pharmaceut Factory Inc ジ低級アルキルフエノ−ル誘導体
DE4119756A1 (de) * 1991-06-15 1992-12-17 Basf Ag Aminoalkylsubstituierte 5-mercaptothiazole, ihre herstellung und verwendung
JPH0859669A (ja) * 1994-06-13 1996-03-05 Takeda Chem Ind Ltd セフェム化合物、その製造法及び剤
US5856347A (en) * 1994-11-29 1999-01-05 Hisamitsu Pharmaceutical Co., Inc. Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof

Also Published As

Publication number Publication date
NZ503828A (en) 2003-03-28
ID23983A (id) 2000-06-14
AU730607B2 (en) 2001-03-08
JP2001522842A (ja) 2001-11-20
PL340540A1 (en) 2001-02-12
NO20002153D0 (no) 2000-04-27
TR200001344T2 (tr) 2000-09-21
ATE374771T1 (de) 2007-10-15
US6040321A (en) 2000-03-21
JP4344084B2 (ja) 2009-10-14
PE131699A1 (es) 2000-03-08
KR20030036862A (ko) 2003-05-09
CN1160343C (zh) 2004-08-04
AU1295599A (en) 1999-05-31
HUP0004559A3 (en) 2002-05-28
BR9814124A (pt) 2000-10-03
WO1999024416A1 (en) 1999-05-20
MY120779A (en) 2005-11-30
IL135589A0 (en) 2001-05-20
PL204642B1 (pl) 2010-01-29
HUP0004559A1 (hu) 2002-04-29
ES2296347T3 (es) 2008-04-16
IL135589A (en) 2004-06-20
TW593292B (en) 2004-06-21
CN1278806A (zh) 2001-01-03
AR017182A1 (es) 2001-08-22
CA2309551C (en) 2006-03-28
RU2211839C2 (ru) 2003-09-10
EP1042307B1 (en) 2007-10-03
KR20010031896A (ko) 2001-04-16
CO4990957A1 (es) 2000-12-26
DE69838515T2 (de) 2008-07-03
ZA9810332B (en) 2000-05-11
CA2309551A1 (en) 1999-05-20
EP1042307A1 (en) 2000-10-11
EG24028A (en) 2008-03-26
CY1107509T1 (el) 2013-03-13
KR100454426B1 (ko) 2004-10-26
EP1042307A4 (en) 2003-01-29
NO316773B1 (no) 2004-05-03
CZ20001744A3 (en) 2001-05-16
PT1042307E (pt) 2007-11-15
CZ297907B6 (cs) 2007-04-25
UY25239A1 (es) 2000-12-29
DK1042307T3 (da) 2008-01-28
DE69838515D1 (de) 2007-11-15

Similar Documents

Publication Publication Date Title
NO20002153L (no) Aminotiazol-inhibitorer for cyklin-avhengige kinaser
NO20002121D0 (no) Benzotiazol-protein-tyrosin-kinaseinhibitorer
NO20015650D0 (no) Pyrrolotriazin-inhibitorer for kinaser
LT2000033A (en) 4-aminothiazole derivatives as inhibitors of cyclin-dependent kinases
DK0925287T3 (da) Heterocykliske metalloproteaseinhibitorer
NO20022864L (no) Aminotiazol inhibitorer av syklin uavhengig kinase
DE69716615D1 (de) Heterozyklische metalloproteaseinhibitoren
ID22982A (id) PIRAZOL-PIRAZOL TERSUBSTITUSI SEBAGAI INHIBITOR KINASE p38
DK0958287T3 (da) Sulfamidmetalloprotease-inhibitorer
FI20001086L (fi) 2-fenyylisubstituoituja imidatsotriatsinoneja fosfodiestraasiinhibiittoreina
FI963597A7 (fi) Isoprenyylitransferaasi-inhibiittoreita
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
DK0858452T3 (da) Thiazolderivater som proteinkinase C-inhibitorer
PT1047450E (pt) Combinacoes inibidor ace - inibidor mmp
TR199802649A3 (tr) Sikline bagli kinazlarin inhibitörleri için baglama esleri.
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
FI971632A7 (fi) 5-lipoksygenaasin inhibiittoreita
ATE225346T1 (de) Fkbp inhibitoren
NO993161D0 (no) Cyklooksygenaseinhibitor
DE69805392D1 (de) Thiazol-Derivate
DK199900134A (da) ãske til vatpinde
FI941265A0 (fi) Heterosyklisiä sulfoniamidotrombiini-inhibiittoreiHeterosyklisiä sulfoniamidotrombiini-inhibiittoreita ta
IDP000027420A (id) Inhibitor-inhibitor kinase pirolotriazin
CY2007006I2 (el) Αναστολεις συνθεσεις απολιποπρωτεϊνης-β

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees